Addyi was first accepted through the FDA in August 2015 to deal with hypoactive sexual motivation ailment (HSDD) in premenopausal Women of all ages. That's just yet another way of claiming it boosts sexual intercourse travel (also known as libido) in Women of all ages who have not reached menopause. It was the first this sort of drug accredited for